Sodium Oxybate
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Sodium Oxybate: From Narcolepsy with Cataplexy to Insomnia
One-Sentence Summary
Sodium oxybate (Xyrem) is a GABA-B/GHB receptor agonist originally developed for narcolepsy with cataplexy, where it improves nocturnal sleep consolidation and reduces cataplexy attacks. The TxGNN model predicts it may also be effective for Insomnia, with 10 relevant clinical trials (including a direct head-to-head RCT against zolpidem) and 13 supporting publications currently identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Narcolepsy with cataplexy (inferred from evidence-pack literature; TFDA license/indication text not available — see Data Gap DG001) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 (1 completed Phase 2 RCT: NCT00383643) |
| Taiwan Market Status | ✗ Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action data is currently flagged as a data gap (DG002). Based on information surfaced in the retrieved literature, sodium oxybate (exogenous GHB) is proposed to act as a GABA-B and GHB receptor agonist, promoting slow-wave sleep, increasing sleep consolidation, and shortening sleep-onset latency (PMID 21476957). This is the same pharmacological basis on which sodium oxybate is used in narcolepsy to consolidate fragmented nocturnal sleep.
Narcolepsy itself is frequently accompanied by sleep-maintenance insomnia as a core symptom (PMID 18805301), which is mechanistically the same target as primary insomnia — difficulty maintaining continuous, restorative sleep. This overlap provides a plausible biological bridge between the approved indication (narcolepsy with cataplexy) and the predicted new indication (insomnia).
This rationale is further supported by a direct, drug-specific RCT: NCT00383643 compared sodium oxybate against zolpidem (a standard insomnia hypnotic) head-to-head in patients with chronic insomnia, indicating the hypothesis has already been tested in a dedicated insomnia population rather than only inferred from narcolepsy trial secondary outcomes.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00383643 | Phase 2 | Completed | 48 | Randomized, double-blind, double-dummy, placebo-controlled trial comparing sodium oxybate (Xyrem) vs zolpidem (Ambien) for chronic insomnia |
| NCT00641186 | Phase 2 | Completed | 30 | Open-label trial of Xyrem for excessive daytime sleepiness and nocturnal sleep disturbance in mild-moderate Parkinson's disease |
| NCT00594256 | Phase 2 | Completed | 8 | Open-label pilot of adjunctive Xyrem for schizophrenia and associated sleep disturbances |
| NCT00330291 | Phase 2 | Withdrawn | 0 | Planned trial of Xyrem for treatment-refractory insomnia due to PTSD |
| NCT04508166 | N/A | Completed | 27 | Deep-sleep-boosting drug conditions (incl. sodium oxybate) tested for prevention of post-traumatic intrusive memories |
| NCT01584934 | Phase 4 | Withdrawn | 0 | Double-blind, placebo-controlled crossover trial of sodium oxybate for fatigue/sleep quality in Chronic Fatigue Syndrome |
| NCT03626727 | Early Phase 1 | Withdrawn | 0 | Open-label trial of sodium oxybate (Xyrem) for post-traumatic narcolepsy and post-traumatic hypersomnia |
| NCT04803786 | N/A | Completed | 110 | Real-world observational study (TENOR) on transitioning narcolepsy patients from Xyrem to Xywav (low-sodium oxybate) |
| NCT06421532 | Phase 2 | Enrolling by invitation | 60 | Low-sodium oxybate (LXB) used to deepen sleep and stimulate glymphatic clearance of Aβ in cerebral amyloid angiopathy |
| NCT02637648 | Phase 3 | Unknown | 60 | Randomized, placebo-controlled trial of oral sodium oxybate for headache and sleep disturbance prophylaxis in cluster headache |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40120323 | 2025 | Cohort Study | J Clin Neurosci | Propensity-matched cohort characterizing treatment patterns of narcolepsy patients on immediate-release sodium oxybate |
| 26171909 | 2015 | Systematic Review (Cochrane) | Cochrane Database Syst Rev | Review of effects of hypnotic/sedating medications, including GHB-class agents, on sleep-disordered breathing |
| 18852348 | 2008 | Open-label Study | Arch Neurol | Sodium oxybate improved excessive daytime sleepiness and polysomnographic sleep measures in Parkinson's disease |
| 20166851 | 2010 | Review | Expert Opin Emerg Drugs | Review of emerging narcolepsy treatments identifying sodium oxybate's role in nocturnal sleep consolidation |
| 20082966 | 2009 | Review | Parkinsonism Relat Disord | Review of daytime sleepiness in Parkinson's disease, discussing sodium oxybate's sleep-consolidating effect |
| 18805301 | 2008 | Review | Rev Neurol | Review of narcolepsy with cataplexy identifying sleep-maintenance insomnia as a core disease feature treated with sodium oxybate |
| 11174231 | 2001 | Case Series | Ann Emerg Med | Characterizes GHB (sodium oxybate) withdrawal syndrome — relevant safety signal for chronic dosing |
| 31526967 | 2019 | Case Report | Sleep Med | Sodium oxybate used to restore sleep initiation in a child with EBV-encephalitis-related sleep-wake regulation lesion |
| 37590830 | 2023 | Review | Continuum (Minneap Minn) | Comprehensive review of pediatric sleep disorders including insomnia and narcolepsy management |
| 21815499 | 2011 | Review | Rev Med Suisse | Review of the bidirectional relationship between chronic pain and sleep disorder, including hypnotic strategies |
Taiwan Market Information
No TFDA authorization records are currently available for sodium oxybate (total_licenses = 0, market status: 未上市 / Not Marketed). No product/dosage-form data could be extracted.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-interaction data (DDI) are not currently available in this evidence pack (DG001, Blocking severity — TFDA label data has not yet been retrieved).
Conclusion and Next Steps
Decision: Hold
Rationale:
- Efficacy evidence is moderate (L2: a completed Phase 2 RCT directly comparing sodium oxybate to zolpidem in chronic insomnia, plus several supportive Phase 2 studies in related sleep-disturbance populations), which alone might support cautious progression.
- However, a Blocking data gap (DG001) means TFDA warnings/contraindications are unavailable, so the mandatory S1 safety pre-screen cannot yet be completed for a CNS depressant with known abuse/dependence and withdrawal potential (PMID 11174231). This gap must be resolved before any "Go" or "Proceed with Guardrails" decision.
To proceed, the following is needed:
- Retrieve and parse the TFDA (or equivalent) package insert for sodium oxybate to complete the S1 safety pre-screen (warnings, contraindications, DDI)
- Confirm detailed mechanism-of-action data via DrugBank API (DG002)
- Assess controlled-substance/REMS-equivalent handling requirements given GHB's abuse and dependence liability
- If safety data clears S1, prioritize NCT00383643-type evidence for a formal L2→L1 evidence upgrade via additional Phase 3 insomnia-specific trials
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.